#Idogen | Explore Tumblr Posts and Blogs

globalinsightsservices · 2 years

Text

Uveitis – Drug Pipeline Landscape, 2022

New York, Global Insight Services have recently published a report on Uveitis – Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.

Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based on which part of the uvea is affected they are anterior uveitis, intermediate uveitis, posterior uveitis, and pan uveitis.

Request for a PDF sample copy of report: https://www.globalinsightservices.com/request-sample/GIS31068

Uveitis is caused by autoimmune diseases like AIDS, Ankylosing spondylitis, Behest’s disease, Lupus and multiple sclerosis, psoriasis, and rheumatoid arthritis and sometimes due to infections. Uveitis may also cause due to cancers that affect the eye, like lymphoma.

Signs and symptoms of Uveitis include spots in the eye that look like tiny rods or chains of transparent bubbles floating around in the field of vision, eye pain and redness, vision problems, including blurred or cloudy vision, photophobia, an abnormal sensitivity to light, headaches.

Report Highlights

Global Insight Service’s, Uveitis – Drug Pipeline Landscape, 2022 report provides an overview of the Uveitis pipeline drugs. This report covers detailed insights on Uveitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Uveitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Some of the key players involved in development of Uveitis therapeutics are :

• ABIONYX Pharma SA • ACELYRIN Inc • Active Biotech AB • Aerie Pharmaceuticals Inc • Afecta Pharmaceuticals Inc • Akari Therapeutics Plc • Alcon Research • Alpine Immune Sciences Inc • Amytrx Therapeutics Inc • Dobecure SL • Eli Lilly and Company • Enzo Biochem Inc • Eyevensys • HanAll Biopharma Co Ltd • Idogen AB • Kodiak Sciences Inc • Mitotech SA • Naegis Pharmaceuticals Inc • Oculis SA • OKYO Pharma Ltd • Oxular Ltd • Parvus Therapeutics Inc

Buy this report: https://www.globalinsightservices.com/checkout/single_user/GIS31068

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Excel data pack included with all report purchases

Robust and transparent research methodology

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us: Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: [email protected] Phone: +1-833-761-1700

0 notes

shinypandaphantom · 3 years

Link

0 notes

awesomechrisharry · 4 years

Text

Hemophilia A Drug Market: Sales, Consumption, Demand and Forecast (2020-2025)

The research report on Hemophilia A Drug market provides a granular analysis of this industry vertical wherein notable market activities are thoroughly researched. Various market segmentations based on product type, application spectrum, and regional terrain are surveyed in-depth, while estimated share held by each segment by the end of forecast period is encompassed in the report.

Request a sample Report of Hemophilia A Drug Market at: https://optimusmarketreports.com/request-sample/1707

This study focuses on the worldwide Hemophilia A Drug Market status, future forecast, growth opportunity, key market and emerging players. The study objectives are to present the Hemophilia A Drug growth in Key regions. so as to supply valuable insight by each key element of the market, the very best and slowest growing market segment within the study is described.

Key Players In the Hemophilia A Drug Market:

Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd, CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, LFB SA, mAbxience SA

You Can Ask For The Discount@ https://optimusmarketreports.com/request_discount/1707

Product Type segmentation:

ATXF-8117

BAY-1093884

BIVV-001

BS-027125

Concizumab

Apart from that the application market is segmented into:

Clinic

Hospital

ASCs

By Geographical Regions:

North America (the U.S., Canada)

Latin America (Brazil, Mexico, Argentina and other countries)

Asia Pacific (India, Japan, China, Australia and New Zealand and other countries)

Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries)

Middle East and Africa (GCC, South Africa, Israel and Other countries)

Reason to get Report:

The report provides granular level information about the market size,regional market share, historic market and forecast.

The report covers complete insights about the competitor’s overview,company share analysis, key market developments, and their key strategies.

The report outlines drivers, restraints, unmet needs, and trends that are presently influence the market.

The report imprint recent innovations, key developments and start-up’s details that are actively working within the market.

The report provides data about market entry strategies, regulatory framework and reimbursement scenario.

To Customize Please Reach Out To Us: https://optimusmarketreports.com/customize_request/1707

About Us:

Optimus Market Research is a premium market research report provider.We have successfully delivered research reports to greater than 800+ global clients.Our primary goal is to achieve in depth research analysis to help our clients with the most accurate business insights.We provide actionable insights through reports to make the right business decisions.

https://optimusmarketreports.com/

([email protected])

#Hemophilia A Drug #Hemophilia A Drug market

0 notes

hello-delveinsight · 4 years

Text

Kidney Transplant Rejection Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

(Albany, US) DelveInsight has launched a new report on "Kidney Transplant Rejection - Market Insights, Epidemiology, and Market Forecast-2030".

DelveInsight's "Kidney Transplant Rejection - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Kidney Transplant Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Companies:

· Alphamab Oncology

· Amgen Inc

· Amyndas Pharmaceuticals LLC

· Astellas Pharma Inc

· Bristol-Myers Squibb Co

· Enceladus Pharmaceuticals BV

· Genzyme Corp

· Hansa Biopharma AB

· Helocyte Biosciences Inc

· Hillhurst Biopharmaceuticals Inc

· Idogen AB

· ITB-Med AB

· JN Biosciences LLC

· Junten Bio Co Ltd

· Kiniksa Pharmaceuticals Ltd

· Kronos Bio Inc

· Kyowa Kirin Co Ltd

· Lyndra Therapeutics Inc.

· Mabtech Ltd

· Medeor Therapeutics Inc

· MyeloRx LLC

· Nekonal Sarl

· NextCell Pharma AB

· Novartis AG

· OSE Immunotherapeutics

· Paranta Biosciences Ltd

· Pharmapraxis

· Rigel Pharmaceuticals Inc

· Sangamo Therapeutics Inc

· Talaris Therapeutics Inc

· TolerogenixX GmbH

· TRACT Therapeutics Inc

· Veloxis Pharmaceuticals AS

· Viela Bio Inc

Request for free sample report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market

View Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market

Scope of the Report

The report covers the descriptive overview of Kidney Transplant Rejection, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

Comprehensive insight has been provided into the Kidney Transplant Rejection epidemiology and treatment in the 7MM

Additionally, an all-inclusive account of both the current and emerging therapies for Kidney Transplant Rejection are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

A detailed review of Kidney Transplant Rejection market; historical and forecasted is included in the report, covering drug outreach in the 7MM

The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Kidney Transplant Rejection market

Request for free sample report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market

View Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market

Key Questions

What was the Kidney Transplant Rejection market share (%) distribution in 2017 and how it would look like in 2030?

What would be the Kidney Transplant Rejection total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?

What are the key findings pertaining to the market across 7MM and which country will have the largest Kidney Transplant Rejection market size during the forecast period (2017-2030)?

At what CAGR, the Kidney Transplant Rejection market is expected to grow in 7MM during the forecast period (2017-2030)?

What would be the Kidney Transplant Rejection market outlook across the 7MM during the forecast period (2017-2030)?

What would be the Kidney Transplant Rejection market growth till 2030, and what will be the resultant market Size in the year 2030?

How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

What is the disease risk, burden and unmet needs of the Kidney Transplant Rejection?

What is the historical Kidney Transplant Rejection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?

What would be the forecasted patient pool of Kidney Transplant Rejection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Kidney Transplant Rejection?

Out of all 7MM countries, which country would have the highest prevalent population of Kidney Transplant Rejection during the forecast period (2017-2030)?

At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Request for free sample report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market

View Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market

Table of Contents:

1. Key Insights

2. Executive Summary of Kidney Transplant Rejection

3. Competitive Intelligence Analysis for Kidney Transplant Rejection

4. Kidney Transplant Rejection: Market Overview at a Glance

4.1. Kidney Transplant Rejection Total Market Share (%) Distribution in 2017

4.2. Kidney Transplant Rejection Total Market Share (%) Distribution in 2030

5. Kidney Transplant Rejection: Disease Background and Overview

6. Patient Journey

7. Kidney Transplant Rejection Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Kidney Transplant Rejection Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

13. Kidney Transplant Rejection: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Kidney Transplant Rejection

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market

About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/

0 notes

upshotre · 5 years

Text

Ekundayo Emerges As TUC Council Chairman

BY TAIWO OGUNMOLA-OMILANI Comrade Gbenga Ekundayo on Thursday emerged as the new Chairman of Trade Union Congress of Nigeria (TUC), Lagos State Council during 2019 triennial delegates conference held in Lagos. The immediate past chairman, Comrade Francis Ogunremi who opted out from the race handed over to the sole candidate, Comrade Ekundayo without conducting any election. Earlier, comrade Ogunremi in his opening address said his three-year tenure was productive but encountered challenges. He appreciated the outgoing Governor, Mr. Akinwunmi Ambode and other members of executive who worked with him. "Permit me to mention that the major challenge is funding as there was no financial support from the centre which left us to approach unwilling employers of labour for support which never happened", he said. The new TUC State Council Chairman was the immediate past secretary of the union. He hails from the PENGASSAN union. In an interview with Comrade Ekundayo, he said the whole effort to emerge as chairman is the effort of the people couple with the immediate past chairman. He therefore appreciated everyone and promise to deliver his best with in collaboration with other executives. Other members of the executives include: Emmanuel Idogen - Vice Chairman, Abiodun Aladetan - Secretary Sule Bishara - Asst. Secretary 1 Oladele Salau - Asst. Secretary 2 Omotola Shonibare - Treasurer Edwin Chidozie Financial Secretary Blessing Awin - Auditor. The immediate past chairman, Francis Ogunremi remains as - Ex-officio including Kazeem Alabi Labaika- Ex-officio, Idowu Oguntuyi - Ex-officio Oluwakemi Jejelowo - Chairperson, women commission, Oluyemisi Adelaja - Secretary, women commission. Dignitaries at the event were the Commissioner for Establishment and Pension, Benson Oke, NLC State Chairperson, Comrade Funmi Sessi. The new Council Chairman, Comrade Gbenga Ekundayo.

Read the full article

0 notes